The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
December 4th 2023
Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.
Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma
November 29th 2023Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.
Read More
FDA Grants Breakthrough Therapy Designation to Epcoritamab for Follicular Lymphoma
November 28th 2023The update followed results from the phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of the drug, including in individuals with relapsed or refractory follicular lymphoma.
Read More
FDA Approves Enzalutamide for Nonmetastatic Castration-Sensitive Prostate Cancer
November 17th 2023The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.
Read More
FDA Approves Capivasertib With Fulvestrant for PIK3CA/AKT1/PTEN Alterations Breast Cancer
November 17th 2023Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.
Read More
Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers
November 9th 2023Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.
Read More
Amivantamab With Lazertinib Can Reduce Risk of Disease Progression By 30% in Patients With NSCLC
October 25th 2023Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.
Read More